AUTHOR=Gu Simeng , Wang Xin , Zhou Jingqiu , Du Shanshan , Niu Ting 

TITLE=Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1373127

DOI=10.3389/fonc.2024.1373127

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>Angioimmunoblastic T-cell lymphoma (AITL) is characterized by high recurrence rates and poor prognosis, and effective first-line treatment is lacking. Recently, histone deacetylase inhibitors (HDACi), such as chidamide, have been found to induce durable remissions in AITL patients.</p></sec><sec><title>Methods</title><p>Patients with untreated AITL from March 2015 to March 2023 were retrospectively collected and divided into chemotherapy (ChT) group and chidamide combined with chemotherapy (C-ChT) group based on the first-line treatment received. The comparison of efficacy and safety between the two groups was conducted.</p></sec><sec><title>Results</title><p>86 patients with newly diagnosed AITL were enrolled, in which 35 patients were in the ChT group and 51 in the C-ChT group. The objective response rate (ORR) of C-ChT group was significantly higher than that of ChT group (84.3% vs. 60%, <italic>P</italic>= 0.011), and had superior progression-free survival (PFS) (27 months vs. 12 months, <italic>P</italic>= 0.025). However, no significant difference in overall survival (OS) was observed between the two groups (<italic>P</italic>= 0.225). In addition, the responding patients who received autologous stem cell transplantation (ASCT) had superior PFS compared to those who did not (<italic>P</italic>= 0.015).</p></sec><sec><title>Conclusions</title><p>Compared with ChT regimen, C-ChT regimen was well tolerated and had superior ORR and PFS in patients with untreated AITL. ASCT may contribute to longer PFS in remission patients.</p></sec>